Cancer at a glance
Cancer represents a significant unmet medical need. Each year,
more than 11 million people around the world are diagnosed with
The World Health Organization (WHO) projects an increase to 16
million people a year over the next 15 years.
The majority of cancer patients die within a short time span of
diagnosis. Seven million people die from cancer every year,
corresponding to 13% of all deaths.
The WHO projects an increase to 10 million by 2020.
Cancer is close to overtaking the position of cardiovascular
diseases as the disease with the highest mortality rate in the
western world, where the most common forms of lethal cancer are
prostate cancer, breast cancer, lung cancer, and colorectal
The strong growth in global sales of cancer therapeutics
witnessed within the past few years is primarily due to the launch
of a number of new and highly specific targeted anti-cancer
In 2006, the global expenditure for oncology drugs was USD 44
billion, up from USD 12 billion in 2000 and the expenditure
increased to USD 65 billion in 2010 and is expected to increase to
USD 72 billion in 2012.
In the years ahead, a continuing trend towards more targeted
cancer therapies is expected. Additionally, a large number of more
biologically specific cancer drugs will reach the market, further
expanding the market for cancer therapeutics.
Topotarget considers itself an important player in the targeted
cancer therapeutics market and is committed to making a substantial
contribution to the development of more effective anti-cancer
The clinical trial process
Topotarget has allocated most of its resources in the clinical
All clinical studies must be conducted by qualified
investigators in accordance with Good Clinical Practice's (GCP)
Clinical studies are typically conducted in three and sometimes
four sequential phases that, however, often overlap or are